Amarin (NASDAQ:AMRN) is now more than $121 million richer, following a public stock offering. The company announced it has closed a 21.7-million share-strong issue of American Depositary Shares, netting a total of around $121.1 million. Additionally, the company's underwriters have been granted a 30-day purchase option for up to an additional 3.255 million American Depositary Shares.
Amarin said it plans to use the proceeds of the issue largely to fund the commercial launch of Vascepa, a treatment that lowers triglycerides.
Citigroup's Global Markets unit, and Leucadia's Jefferies, were the joint-book running managers of the offering.
Prior to the issue, Amarin had around 150.7 million shares outstanding. Its stock's most recent closing price was $5.27 per share.
Fool contributor Eric Volkman has no position in any stocks mentioned. The Motley Fool owns shares of Citigroup. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Growth Stocks to Own in 2018
If you're looking for outstanding growth vehicles to own next year, these three biotech stocks are worth checking out.
3 Small-Cap Biotech Stocks That Could Be Big Winners in 2018
If you're on the hunt for small-cap biotechs that could be big winners next year, Amarin, MannKind Corp., and 22nd Century Group need to be on your radar right now.
Here's Why Amarin Corporation plc Is on the Rise Today
Second-quarter Vascepa sales were even better than expected.